Skip to main content

Advertisement

SpringerLink
Log in

VEGF165 attenuates the Th17/Treg imbalance that exists when transplanting allogeneic skeletal myoblasts to treat acute myocardial infarction

  • Original Research Paper
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Objectives

To investigate whether Th17/Treg imbalance exists, and whether VEGF165 attenuates the imbalance in allogeneic skeletal myoblast transplantation (allo-SMT) for acute myocardial infarction (AMI).

Methods

On days 1, 2, 4, and 7 after allo-SMT, the percentages and ratios of Th17 and Treg cells were analyzed by flow cytometry in three groups—the AMI group, the AMI-S group (allo-SMT) and the AMI-V group (with VEGF165 treatment). Subsequently, related proinflammatory and regulatory cytokines and key transcription factors, ROR-γt mRNA and Foxp3 mRNA expression, were examined by Bio-plex and real-time polymerase chain reaction, respectively.

Results

On days 1, 2, 4, and 7, the percentage of Tregs, related cytokine concentrations and transcript factor Foxp3 mRNA in the AMI-S group were lower than those in the AMI group, while those in the AMI-V group were higher than those in the AMI group. However, the percentage of Th17 cells, related cytokine concentrations and ROR-γt mRNA in the AMI-S group were higher than those in the AMI group; those in the AMI-V group were lower than those in the AMI group. Compared with the AMI group, the ratios of Th17/Treg cells significantly increased in the AMI-S group and decreased in the AMI-V group.

Conclusions

Th17/Treg imbalance participated in the formation and development of the inflammatory and immune response after allo-SMT. However, transfected VEGF165 was able to relieve the severity of the Th17/Treg imbalance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Imanishi Y, Miyagawa S, Saito A, et al. Allogenic skeletal myoblast transplantation in acute myocardial infarction model rats. Transplantation. 2011;91:425–31.

    PubMed  Google Scholar 

  2. Li N, Bian H, Zhang J, et al. The Th17/Treg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction. Clin Chim Acta. 2010;411:1963–8.

    Article  PubMed  CAS  Google Scholar 

  3. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity. 2009;30:626–35.

    Article  PubMed  CAS  Google Scholar 

  4. Cheng X, Liao YH, Ge H, et al. TH1/TH2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation. J Clin Immunol. 2005;25:246–53.

    Article  PubMed  CAS  Google Scholar 

  5. Pinto RA, Arredondo SM, Bono MR, et al. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol. Pediatrics. 2006;117:e878–86.

    Article  PubMed  Google Scholar 

  6. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21:467–76.

    Article  PubMed  CAS  Google Scholar 

  7. LeibundGut-Landmann S, Gross O, Robinson MJ, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol. 2007;8:630–8.

    Article  PubMed  CAS  Google Scholar 

  8. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345–50.

    Article  PubMed  CAS  Google Scholar 

  9. Sonderegger I, Rohn TA, Kurrer MO, et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol. 2006;36:2849–56.

    Article  PubMed  CAS  Google Scholar 

  10. Xie JJ, Wang J, Tang TT, et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(−/−) mice. Cytokine. 2010;49:185–93.

    Article  PubMed  CAS  Google Scholar 

  11. Chen X, Vodanovic-Jankovic S, Johnson B, et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 2007;110:3804–13.

    Article  PubMed  CAS  Google Scholar 

  12. Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol. 2009;10:778–85.

    Article  PubMed  CAS  Google Scholar 

  13. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485–517.

    Article  PubMed  CAS  Google Scholar 

  14. Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127:89–97.

    Article  PubMed  CAS  Google Scholar 

  15. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455–8.

    Article  PubMed  CAS  Google Scholar 

  16. Choi MS, Lim JY, Cho BS, et al. The role of regulatory T cells during the attenuation of graft-versus-leukemia activity following donor leukocyte infusion in mice. Leuk Res. 2011;35:1549–56.

    Article  PubMed  CAS  Google Scholar 

  17. Maruyama T, Kono K, Mizukami Y, et al. Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci. 2010;101:1947–54.

    Article  PubMed  CAS  Google Scholar 

  18. Verma ND, Plain KM, Nomura M, et al. CD4+CD25+ T cells alloactivated ex vivo by IL-2 or IL-4 become potent alloantigen-specific inhibitors of rejection with different phenotypes, suggesting separate pathways of activation by Th1 and Th2 responses. Blood. 2009;113:479–87.

    Article  PubMed  CAS  Google Scholar 

  19. Eastaff-Leung N, Mabarrack N, Barbour A, et al. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol. 2010;30:80–9.

    Article  PubMed  CAS  Google Scholar 

  20. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–8.

    Article  PubMed  CAS  Google Scholar 

  21. Zhou L, Lopes JE, Chong MM, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008;453:236–40.

    Article  PubMed  CAS  Google Scholar 

  22. McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol. 2007;8:1390–7.

    Article  PubMed  CAS  Google Scholar 

  23. Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26:371–81.

    Article  PubMed  CAS  Google Scholar 

  24. Zhu K, Guo C, Lai H, et al. Novel hyperbranched polyamidoamine nanoparticles for transfecting skeletal myoblasts with vascular endothelial growth factor gene for cardiac repair. J Mater Sci Mater Med. 2011;11:2477–85.

    Article  Google Scholar 

  25. Zhang Y, Wang L, Zhang M, et al. Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF–EGFR–PI3K–Akt–Erk pathway. J Cell Physiol. 2012;227:35–43.

    Article  PubMed  CAS  Google Scholar 

  26. Min CK, Kim SY, Lee MJ, et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:149–56.

    Article  PubMed  CAS  Google Scholar 

  27. Wang W, Shao S, Jiao Z et al. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int. 2012; 32(4): 887−93

    Google Scholar 

  28. Chen LN, Conghua W, Leng N, Zhu P. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol. 2011;31:596–605.

    Article  CAS  Google Scholar 

  29. Takatsuka H, Takemoto Y, Yamada S, et al. Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transplant. 2000;26:419–26.

    Article  PubMed  CAS  Google Scholar 

  30. Quaglino P, Bergallo M, Ponti R, et al. Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response. Dermatology. 2011;223:57–67.

    Article  PubMed  CAS  Google Scholar 

  31. Yi T, Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009;114:3101–12.

    Article  PubMed  CAS  Google Scholar 

  32. Shi Y, Fukuoka M, Li G, et al. Regulatory T cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor beta-coxsackie-adenovirus receptor pathway. Circulation. 2010;121:2624–34.

    Article  PubMed  CAS  Google Scholar 

  33. Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut. 2009;58:1152–67.

    Article  PubMed  CAS  Google Scholar 

  34. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med. 2002;196:851–7.

    Article  PubMed  CAS  Google Scholar 

  35. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875–86.

    Article  PubMed  CAS  Google Scholar 

  36. Chatenoud L. Natural and induced T CD4+CD25+FOXP3+ regulatory T cells. Methods Mol Biol. 2011;677:3–13.

    Article  PubMed  Google Scholar 

  37. Venet F, Pachot A, Debard AL, et al. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J Immunol. 2006;177:6540–7.

    PubMed  CAS  Google Scholar 

  38. Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007;445:771–5.

    Article  PubMed  CAS  Google Scholar 

  39. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239–44.

    Article  PubMed  CAS  Google Scholar 

  40. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–9.

    Article  PubMed  CAS  Google Scholar 

  41. Barry S, Ounzain S, McCormick J et al. Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury. Int J Cardiol 2011. [Epub ahead of print].

  42. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol. 2007;148:32–46.

    Article  PubMed  CAS  Google Scholar 

  43. Kupatt C, Hinkel R, Vachenauer R, et al. VEGF165 transfection decreases postischemic NF-kappa B-dependent myocardial reperfusion injury in vivo: role of eNOS phosphorylation. FASEB J. 2003;17:705–7.

    PubMed  CAS  Google Scholar 

  44. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597–601.

    Article  PubMed  CAS  Google Scholar 

  45. Yin H, Chao L, Chao J. Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Life Sci. 2008;82:156–65.

    Article  PubMed  CAS  Google Scholar 

  46. Awane M, Andres PG, Li DJ, Reinecker HC. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol. 1999;162:5337–44.

    PubMed  CAS  Google Scholar 

  47. Chakrabarti S, Rizvi M, Morin K, et al. The role of CD40L and VEGF in the modulation of angiogenesis and inflammation. Vascul Pharmacol. 2010;53:130–7.

    Article  PubMed  CAS  Google Scholar 

  48. Chakrabarti S, Rizvi M, Pathak D, et al. Hypoxia influences CD40-CD40L mediated inflammation in endothelial and monocytic cells. Immunol Lett. 2009;122:170–84.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are grateful for the support of Natural Science Foundation of Shanghai (Grant No. 10ZR1406200100), and the National Natural Science Foundation of China (Grant No. 81000042).

Author information

Authors and Affiliations

  1. Department of Cardiac Surgery, Zhongshan Hospital, Fudan University & Shanghai Institute of Cardiovascular Diseases, No. 180, Fenglin Road, Xuhui District, Shanghai, 200032, People’s Republic of China

    Ruijun Liu, Changfa Guo, Chen Yang, Demin Xu & Chunsheng Wang

Authors
  1. Ruijun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Changfa Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chen Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Demin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chunsheng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ruijun Liu, Changfa Guo or Chunsheng Wang.

Additional information

Responsible Editor: Liwu Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, R., Guo, C., Yang, C. et al. VEGF165 attenuates the Th17/Treg imbalance that exists when transplanting allogeneic skeletal myoblasts to treat acute myocardial infarction. Inflamm. Res. 62, 69–79 (2013). https://doi.org/10.1007/s00011-012-0553-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-012-0553-4

Keywords

Search

Navigation